|
Interferon beta-1b
resources
|
|
|
|
|
|
DRUG INFO
Interferon beta-1b
Drug Name:
Interferon beta-1b
Indication: For treatment of relapsing/remitting multiple sclerosis
Pharmacology: Interferon beta upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Type I interferons also induce the synthesis of several key antiviral mediators including 2'-5' oligoadenylate synthetase (2'-5' A synthetase), beta-2 microglobulin, neopterin and protein kinase R.
Mechanism Of Action: Interferon beta binds to type I interferon receptors (IFNAR1 and IFNAR2c) which activate two Jak (Janus kinase) tyrosine kinases (Jak1 and Tyk2). These transphosphorylate themselves and phosphorylate the receptors. The phosphorylated INFAR receptors then bind to Stat1 and Stat2 (signal transducers and activators of transcription)which dimerize and activate multiple (~100) immunomodulatory and antiviral proteins. Interferon beta binds more stably to type I interferon receptors than interferon alpha.
Drug Category: Antiviral Agents; Immunomodulatory Agents; unclassified therapeutic agents (92:00.00)
Brand Names/Synonyms: Interferon beta precursor;IFN-beta;Fibroblast interferon; Betaseron (Chiron Corp)
Dosage Forms: LIQUID;POWDER FOR SOLUTION
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Human interferon beta
Chemical Formula: C908H1408N246O253S6
Half Life: Not Available
Drug Type: Approved Drug
# Accession No: BIOD00078
CAS Registry Number: 96778-78-8; 145155-23-3
|
|
|
|
|
|
Interferon beta-1b News
(When available)
Rivals Glaxo, Novartis reported close to making bids for Serono Jan 12, 2006
Boston Globe, Schering AG's Betaseron had sales of $944 million. ... Existing MS medicines, including Rebif, Avonex, and Betaseron, all have to be injected. ...
Medicare expands tier pricing system Jan 3, 2006
USA Today ...are such expensive treatments as Remicade and Enbrel for rheumatoid arthritis, Procrit and Aranesp for anemia and Copaxone and Betaseron for multiple sclerosis ...
|
|
|
